Product Information

CHLORDIAZEPOXIDE-CLIDINIUM CAP is a generic product labeled by Aurobindo Pharma Limited, priced at $0.2858 per EA under NDC 59651052401. Its NADAC has been published 117 times since Aug 28, 2024.

FDA first approved this application on Sep 14, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

CHLORDIAZEPOXIDE-CLIDINIUM CAP

Chlordiazepoxide Hydrochloride and Clidinium Bromide
$0.2858per EA
DEA Schedule CIV

Strength

5; 2.5 mg/1; mg/1

NDC

59651052401

Classification

Generic

Dosage Form

CAPSULE

Route

ORAL

Effective Date

11/18/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA216419

FDA Approved

9/14/2023

TE Code

AB

On Market Since

9/14/2023

Pharmacological Classes

Anticholinergic
Benzodiazepine
Benzodiazepines
Cholinergic Antagonists
Decreased Parasympathetic Acetylcholine Activity
Digestive/GI System Activity Alteration
GI Motility Alteration

Price Statistics

The NADAC for CHLORDIAZEPOXIDE-CLIDINIUM CAP has been published 117 times since Aug 28, 2024, and over the history we have for it it has declined 33.5%. The table below summarizes its recorded NADAC range and movement.

Current price$0.2858 per EA
All-time high$0.5272 (Oct 16, 2024)
All-time low$0.2405 (Mar 18, 2026)
52-week high$0.2858
52-week low$0.2405
Median price$0.2760
Average price$0.2996
Largest weekly change-26.2% (Nov 20, 2024)
Weeks tracked117
Tracking sinceAug 28, 2024

Price History

1W

+3.6%

1M

+11.6%

3M

+12.3%

6M

+5.3%

1Y

+15.2%

3Y

N/A

5Y

N/A

All

-33.5%

Generic Alternatives

The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of CHLORDIAZEPOXIDE-CLIDINIUM CAP?

The current National Average Drug Acquisition Cost (NADAC) for CHLORDIAZEPOXIDE-CLIDINIUM CAP, manufactured by Aurobindo Pharma Limited, is $0.2858 per EA (NDC 59651052401), effective Nov 18, 2026.

How has the price of CHLORDIAZEPOXIDE-CLIDINIUM CAP changed over time?

Over the history we have for it, the NADAC for CHLORDIAZEPOXIDE-CLIDINIUM CAP has declined 33.5%. It has been tracked across 117 weekly CMS publications since Aug 28, 2024.

What are the highest and lowest recorded NADAC prices for CHLORDIAZEPOXIDE-CLIDINIUM CAP?

Since Aug 28, 2024, the NADAC for CHLORDIAZEPOXIDE-CLIDINIUM CAP has ranged from a low of $0.2405 (Mar 18, 2026) to a high of $0.5272 (Oct 16, 2024), with a median of $0.2760 per EA.

Are there cheaper alternatives to CHLORDIAZEPOXIDE-CLIDINIUM CAP?

4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CHLORDIAZEPOXIDE-CLIDINIUM CAP in a comparable dosage form, but none are currently priced below it.

Who manufactures CHLORDIAZEPOXIDE-CLIDINIUM CAP?

CHLORDIAZEPOXIDE-CLIDINIUM CAP (NDC 59651052401) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.